## Sandra Nuyts

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5048201/publications.pdf

Version: 2024-02-01

128	2,155	21 h-index	43
papers	citations		g-index
181	181	181	3212
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. European Radiology, 2010, 20, 1703-1714.	4.5	182
2	Dysphagia After Chemoradiotherapy for Head-and-Neck Squamous Cell Carcinoma: Dose–Effect Relationships for the Swallowing Structures. International Journal of Radiation Oncology Biology Physics, 2009, 75, 385-392.	0.8	163
3	Advances in Radiotherapy for Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3277-3284.	1.6	142
4	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 2016, 8, 41.	3.7	100
5	p16INK4a Impairs Homologous Recombination–Mediated DNA Repair in Human Papillomavirus–Positive Head and Neck Tumors. Cancer Research, 2014, 74, 1739-1751.	0.9	99
6	Integrating pretreatment diffusion weighted MRI into a multivariable prognostic model for head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2014, 110, 429-434.	0.6	90
7	Benefits of deep learning for delineation of organs at risk in head and neck cancer. Radiotherapy and Oncology, 2019, 138, 68-74.	0.6	79
8	Long-term follow-up of 123 patients with adenocarcinoma of the sinonasal tract treated with endoscopic resection and postoperative radiation therapy. Head and Neck, 2016, 38, 294-300.	2.0	71
9	Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. Oncotarget, 2017, 8, 81662-81678.	1.8	61
10	Impact of Adding Concomitant Chemotherapy to Hyperfractionated Accelerated Radiotherapy for Advanced Head-and-Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1088-1095.	0.8	59
11	Interobserver variability in delineation of target volumes in head and neck cancer. Radiotherapy and Oncology, 2019, 137, 9-15.	0.6	59
12	Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiotherapy and Oncology, 2013, 109, 323-329.	0.6	58
13	Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiotherapy and Oncology, 2017, 122, 171-177.	0.6	56
14	Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?. Cancers, 2017, 9, 135.	3.7	49
15	Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac. Radiotherapy and Oncology, 2018, 128, 479-484.	0.6	49
16	Low-Level Laser Therapy Stimulates Proliferation in Head and Neck Squamous Cell Carcinoma Cells. Frontiers in Oncology, 2018, 8, 343.	2.8	41
17	Up-front and Salvage Transoral Robotic Surgery for Head and Neck Cancer: A Belgian Multicenter Retrospective Case Series. Frontiers in Oncology, 2017, 7, 15.	2.8	29
18	Ethanol exposure increases mutation rate through error-prone polymerases. Nature Communications, 2020, 11, 3664.	12.8	29

#	Article	IF	Citations
19	Interobserver variability in organ at risk delineation in head and neck cancer. Radiation Oncology, 2021, 16, 120.	2.7	29
20	Radiosensitization approaches for HPVâ€positive and HPVâ€negative head and neck squamous carcinomas. International Journal of Cancer, 2020, 146, 1075-1085.	5.1	27
21	Randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma; update of the long-term tumor outcome. Radiotherapy and Oncology, 2020, 143, 24-29.	0.6	26
22	Recurrence patterns after a decreased dose of 40 Gy to the elective treated neck in head and neck cancer. Radiotherapy and Oncology, 2017, 123, 419-423.	0.6	25
23	Patient Selection in Human Papillomavirus Related Oropharyngeal Cancer: The Added Value of Prognostic Models in the New TNM 8th Edition Era. Frontiers in Oncology, 2018, 8, 273.	2.8	21
24	Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?. Oral Oncology, 2020, 102, 104561.	1.5	21
25	Deep learning for elective neck delineation: More consistent and time efficient. Radiotherapy and Oncology, 2020, 153, 180-188.	0.6	21
26	The role of stem cells in the prevention and treatment of radiationâ€induced xerostomia in patients with head and neck cancer. Cancer Medicine, 2016, 5, 1147-1153.	2.8	20
27	Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches. Frontiers in Oncology, 2018, 8, 439.	2.8	20
28	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapyÂ(PRESTO trial). Trials, 2020, 21, 237.	1.6	20
29	Dual role for p16 in the metastasis process of HPV positive head and neck cancers. Molecular Cancer, 2017, 16, 113.	19.2	18
30	Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization. Radiotherapy and Oncology, 2018, 128, 161-166.	0.6	18
31	Does intensity-modulated radiation therapy lower the risk of osteoradionecrosis of the jaw? A long-term comparative analysis. International Journal of Oral and Maxillofacial Surgery, 2019, 48, 1387-1393.	1.5	18
32	The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Scientific Reports, 2020, 10, 16208.	3.3	18
33	Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review. Advances in Therapy, 2021, 38, 90-108.	2.9	18
34	Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. Cancers, 2021, 13, 1254.	3.7	18
35	Redefining the target early during treatment. Can we visualize regional differences within the target volume using sequential diffusion weighted MRI?. Radiotherapy and Oncology, 2014, 110, 329-334.	0.6	17
36	Clinical Progress in Proton Radiotherapy: Biological Unknowns. Cancers, 2021, 13, 604.	3.7	17

#	Article	IF	Citations
37	Differences in human papillomavirus–positive and –negative head and neck cancers in Belgium: an 8-year retrospective, comparative study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 456-460.	0.4	16
38	Towards 3D printed multifunctional immobilization for proton therapy: Initial materials characterization. Medical Physics, 2016, 43, 5392-5402.	3.0	15
39	Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers. International Journal of Molecular Sciences, 2021, 22, 1504.	4.1	15
40	First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation. Journal of Chemotherapy, 2016, 28, 242-246.	1.5	14
41	Photodynamic Therapy as an Alternative Therapeutic Tool in Functionally Inoperable Oral and Oropharyngeal Carcinoma: A Single Tertiary Center Retrospective Cohort Analysis. Frontiers in Oncology, 2021, 11, 626394.	2.8	14
42	Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer. European Thyroid Journal, 2018, 7, 211-217.	2.4	13
43	Hypoxia and Its Influence on Radiotherapy Response of HPV-Positive and HPV-Negative Head and Neck Cancer. Cancers, 2021, 13, 5959.	3.7	13
44	Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis. Radiation Oncology, 2014, 9, 248.	2.7	12
45	Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc. Radiation Oncology, 2017, 12, 59.	2.7	12
46	Obstructive sleep apnea in head and neck cancer survivors. Supportive Care in Cancer, 2021, 29, 279-287.	2.2	12
47	Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers. Oncotarget, 2016, 7, 38785-38795.	1.8	12
48	Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer., 2011, 7, 1-6.		12
49	Prognostic Significance of Glutathione Peroxidase Levels (GPx1) in Head and Neck Cancers. Frontiers in Oncology, 2017, 7, 84.	2.8	11
50	Noncutaneous head and neck cancer in solid organ transplant patients: Single center experience. Oral Oncology, 2014, 50, 263-268.	1.5	10
51	The DNA Damage Response Is Differentially Involved in HPV-Positive and HPV-Negative Radioresistant Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3717.	3.7	10
52	Transoral robotic surgery ( <scp>TORS</scp> ) using the da Vinci Xi: prospective analysis of feasibility, safety, and outcomes. Head and Neck, 2022, 44, 143-157.	2.0	10
53	Clinical Implementation of DeepVoxNet for Auto-Delineation of Organs at Risk in Head and Neck Cancer Patients in Radiotherapy. Lecture Notes in Computer Science, 2018, , 223-232.	1.3	9
54	Improved survival in patients with head and neck cancerÂtreated in higher volume centres: A population-based study in Belgium. European Journal of Cancer, 2020, 130, 81-91.	2.8	9

#	Article	IF	Citations
55	Current indications for adjuvant treatment following transoral laser microsurgery of early and intermediate laryngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 79-85.	1.8	9
56	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. Cancers, 2022, 14, 2587.	3.7	9
57	Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity. Radiotherapy and Oncology, 2017, 124, 220-224.	0.6	8
58	Molecular Markers and Chemotherapy for Advanced Salivary Cancer. Current Otorhinolaryngology Reports, 2014, 2, 85.	0.5	7
59	Ethanol-Induced Cell Damage Can Result in the Development of Oral Tumors. Cancers, 2021, 13, 3846.	3.7	7
60	OC-0278 Accelerated CH-RT with/without nimorazole for p16- HNSCC: the randomized DAHANCA 29-EORTC 1219 trial. Radiotherapy and Oncology, 2021, 161, S187-S188.	0.6	7
61	Head and Neck Cancer in Belgium: Quality of Diagnostic Management and Variability Across Belgian Hospitals Between 2009 and 2014. Frontiers in Oncology, 2019, 9, 1006.	2.8	6
62	Segmentation of head-and-neck organs-at-risk in longitudinal CT scans combining deformable registrations and convolutional neural networks. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2020, 8, 519-528.	1.9	6
63	Transoral Laser Microsurgery (TLM) for Glottic Cancer: Prospective Assessment of a New Pathology Workup Protocol. Frontiers in Surgery, 2020, 7, 56.	1.4	6
64	Prognostic value of aÂ15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy. Strahlentherapie Und Onkologie, 2020, 196, 552-560.	2.0	6
65	Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer. Frontiers in Oncology, 2021, 11, 720052.	2.8	6
66	CT-based follow-up following radiotherapy or radiochemotherapy for locally advanced head and neck cancer; outcome and development of a prognostic model for regional control. British Journal of Radiology, 2016, 89, 20160492.	2.2	5
67	Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?. British Journal of Radiology, 2017, 90, 20170596.	2,2	5
68	Validation of the total dysphagia risk score (TDRS) in head and neck cancer patients in a conventional and a partially accelerated radiotherapy scheme. Radiotherapy and Oncology, 2016, 118, 293-297.	0.6	4
69	Modern radiotherapy techniques versus three-dimensional conformal radiotherapy for head and neck cancer. The Cochrane Library, 0, , .	2.8	4
70	Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer. British Journal of Radiology, 2018, 91, 20180155.	2.2	4
71	Clinically Relevant Response to Cisplatin-5-Fluorouracyl in Intestinal-Type Sinonasal Adenocarcinoma with Loss of Vision: A Case Report. Case Reports in Oncology, 2019, 12, 277-281.	0.7	4
72	Contemporary management of the neck in nasopharyngeal carcinoma. Head and Neck, 2021, 43, 1949-1963.	2.0	4

#	Article	IF	Citations
73	Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. Head and Neck, 2021, 43, 2807-2821.	2.0	4
74	Patterns and quality of care for head and neck cancer in Belgium: A populationâ€based study. European Journal of Cancer Care, 2021, 30, e13454.	1.5	4
75	Postoperative accelerated radiotherapy (POPART) versus conventional postoperative radiotherapy (CPORT) in squamous cell head and neck cancer: A multicenter prospective randomized study of the Dutch Head and Neck Cooperative Study Group Journal of Clinical Oncology, 2010, 28, 5508-5508.	1.6	4
76	A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. Frontiers in Oncology, 2022, 12, 761428.	2.8	4
77	Correlation of Patient- and Physician-Scored Dysphagia with Videofluoroscopies in Patients Treated with Radiotherapy for Head and Neck Cancer. Dysphagia, 2018, 33, 684-690.	1.8	3
78	Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. Quality of Life Research, 2021, 30, 117-127.	3.1	3
79	Virtual monoenergetic micro-CT imaging in mice with artificial intelligence. Scientific Reports, 2022, 12, 2324.	3.3	3
80	Using a Closed Analytical Expression to Determine Biological Effects Depending on Radiation Spectrum and Oxygen Level. International Journal of Radiation Oncology Biology Physics, 2013, 87, S97.	0.8	2
81	Introduction of a New Pathology Workup Protocol for Glottic Cancer Treated With Transoral Laser Microsurgery (TLM): Prospective Analysis of Oncological Outcomes and Matched Case-Control Study. Frontiers in Oncology, 2021, 11, 685255.	2.8	2
82	An Integrated Approach Reveals DNA Damage and Proteotoxic Stress as Main Effects of Proton Radiation in S. cerevisiae. International Journal of Molecular Sciences, 2022, 23, 5493.	4.1	2
83	SP-0393: The challenges of ART from a physician's perspective. Radiotherapy and Oncology, 2016, 119, S184.	0.6	1
84	OC-0452: Prospective randomized adaptive dose-de-escalation in the elective neck: late toxicity and control. Radiotherapy and Oncology, 2016, 119, S211-S212.	0.6	1
85	The true value of altered fractionation in head and neck cancer. Lancet Oncology, The, 2017, 18, 1147-1148.	10.7	1
86	In Regard to Bibault etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 100, 807-808.	0.8	1
87	Does the total dysphagia risk score correlate with swallowing function examined by videofluoroscopy?. British Journal of Radiology, 2018, 91, 20170714.	2.2	1
88	In Regard to Maguire etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 101, 746-747.	0.8	1
89	Radiation Treatment for Inoperable Local Relapse of Parathyroid Carcinoma With Symptomatic Hypercalcemia: A Case Report. Frontiers in Oncology, 2021, 11, 733772.	2.8	1
90	109 Microsatellite alterations (MSI/LOH) in head and neck squamous cell carcinoma: Does a correlation exist with hypoxia as measured by pimonidazole?. Radiotherapy and Oncology, 2006, 78, S34.	0.6	0

#	Article	IF	Citations
91	179 Microsatellite alterations in head and neck squamous cell carcinoma: comparison of the sensitivity of a novel literature-based microsatellite panel versus the bethesda reference panel. Radiotherapy and Oncology, 2006, 78, S61-S62.	0.6	0
92	P65 Radiosensitization by histone deacetylase inhibitors $+/\hat{a}$ demethylating agents in head and neck cancer cell lines. European Journal of Cancer, Supplement, 2007, 5, 23.	2.2	0
93	The prognostic value of FMISO and FDG pet in locally advanced head and neck cancer (HNC). Radiotherapy and Oncology, 2007, 82, S41.	0.6	0
94	Radiotherapy and chemoradiotherapy of the head and neck. , 2008, , 19-34.		0
95	Dose Prescription and Treatment Planning Based on [18F]FMISO-PET Hypoxia. International Journal of Radiation Oncology Biology Physics, 2009, 75, S617-S618.	0.8	0
96	DIFFUSION-WEIGHTED MRI (DWI)-GUIDED RADIOTHERAPY FOR HEAD AND NECK CANCER. Radiotherapy and Oncology, 2009, 92, S9-S10.	0.6	0
97	BIOLOGICALLY OPTIMISED IMRT BASED ON MOLECULAR IMAGING OF TUMOUR HYPOXIA. Radiotherapy and Oncology, 2009, 92, S199-S200.	0.6	0
98	Estimating Microscopic Dose Distribution Variations for Nano-particle Enhanced Radiation Therapy using GaF Chromic Film and Transmission Electron Microscopy (TEM). International Journal of Radiation Oncology Biology Physics, 2010, 78, S831-S832.	0.8	0
99	8515 POSTER DISCUSSION A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach. European Journal of Cancer, 2011, 47, S548.	2.8	0
100	P16 IMMUNOHISTOCHEMISTRY AND HPV-PCR FOR RESPONSE PREDICTION AFTER RADIOTHERAPY IN HNSCC. Radiotherapy and Oncology, 2011, 98, S10.	0.6	0
101	CORRELATION OF HPV STATUS TO PRETREATMENT FUNCTIONAL IMAGING IN PATIENTS WITH OROPHARYNGEAL CANCER. Radiotherapy and Oncology, 2011, 98, S44.	0.6	0
102	332 oral QUANTIFICATION OF DIFFUSION-WEIGHTED MRI FOR TREATMENT RESPONSE ASSESSMENT IN HEAD AND NECK CANCER. Radiotherapy and Oncology, 2011, 99, S132-S133.	0.6	0
103	836 poster FUNCTIONAL MR IMAGING IN PATIENTS WITH OROPHARYNGEAL CANCER AND THE RELATION TO HPV Radiotherapy and Oncology, 2011, 99, S325.	0.6	0
104	850 poster P16 IMMUNOHISTOCHEMISTRY AND HPV-PCR FOR RESPONSE PREDICTION AFTER RADIOTHERAPY IN HNSCC. Radiotherapy and Oncology, 2011, 99, S329-S330.	0.6	0
105	1120 poster MICROSCOPIC AND SPECTRAL DOSIMETRY USING GAF-CHROMIC FILMS AND SURFACE ELECTRON MICROSCOPY. Radiotherapy and Oncology, 2011, 99, S417-S418.	0.6	0
106	OP 75 An unbiased shRNA based lentiviral screen identifies tyrosine kinases that are important for survival and radioresistance in Head and Neck Squamous Cell Carcinoma. European Journal of Cancer, 2011, 47, S9-S10.	2.8	0
107	Elevated carcinoembryonic antigen tumour marker caused by head and neck cancer: A case report and literature study. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 106-110.	1.4	O
108	EP-1040: Development of a CT-based prognostic model for regional control in head and neck cancer after RT. Radiotherapy and Oncology, 2016, 119, S502-S503.	0.6	0

#	Article	IF	CITATIONS
109	OC-0164: Integrate range shifting in immobilisation for proton therapy: 3D printed materials characterisation. Radiotherapy and Oncology, 2016, 119, S77.	0.6	O
110	OC-0439: Localization of p16 expression is an important factor to determine radiotherapy response in HNSCC. Radiotherapy and Oncology, 2016, 119, S204-S205.	0.6	0
111	PV-0517: Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy. Radiotherapy and Oncology, 2016, 119, S244-S245.	0.6	0
112	SP-0398: Novel developments in the radiobiology of HPV-positive head and neck tumours. Radiotherapy and Oncology, 2017, 123, S212.	0.6	0
113	EP-1590: Can bolus range shifting improve plan quality in the IMPT of head and neck cancer?. Radiotherapy and Oncology, 2017, 123, S856-S857.	0.6	0
114	Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al Radiotherapy and Oncology, 2017, 124, 336.	0.6	0
115	OC-045: Recurrence patterns after 40 Gy to the elective treated neck in head and neck cancer Radiotherapy and Oncology, 2017, 122, 24-25.	0.6	0
116	Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al Radiotherapy and Oncology, 2018, 126, 571-572.	0.6	0
117	SP-0116: The status of reduced RT dose therapy for HPV + cancer. Radiotherapy and Oncology, 2018, 127, S60-S61.	0.6	0
118	OC-0491: CRISPR-Cas9 screen of DNA damage response reveals novel radiosensitizers for head and neck cancers. Radiotherapy and Oncology, 2018, 127, S252-S253.	0.6	0
119	OC-0514: VMAT treatment planning for head-and-neck cancer with the novel fast-rotating linac halcyon. Radiotherapy and Oncology, 2018, 127, S269-S270.	0.6	0
120	EP-1170: Clinical factors impacting on late dysphagia in head and neck cancer following radiotherapy. Radiotherapy and Oncology, 2018, 127, S655.	0.6	0
121	PO-114 Variability in target volume delineation in Head and Neck cancer: Results of a national study. Radiotherapy and Oncology, 2019, 132, 58-59.	0.6	0
122	EP-2026 Diffusion weighted textural differences between p16 positive and negative oropharyngeal carcinoma. Radiotherapy and Oncology, 2019, 133, S1111-S1112.	0.6	0
123	PO-0723 Benefits of deep learning for delineation of organs at risk in head and neck cancer. Radiotherapy and Oncology, 2019, 133, S371.	0.6	0
124	Bilateral radiation-induced squamous cell carcinomas of the external auditory canal 30 years after radiotherapy for a pituitary adenoma: a case report. Tumori, 2019, 105, NP4-NP7.	1.1	0
125	SU-GG-J-124: On the Search of the Ideal Radiation Source for Gold Nano-Particle Enhanced Radiation Treatment. Medical Physics, 2010, 37, 3174-3174.	3.0	0
126	SU-E-T-105: Using GaF-Chromic Film to Determine Microscopic Dose Enhancement of Gold Nanoparticles. Medical Physics, 2011, 38, 3510-3510.	3.0	0

## Sandra Nuyts

#	Article	IF	CITATIONS
127	Intensity modulated radiotherapy for head-and-neck cancer: discussing safety of modern radiation techniques. Translational Cancer Research, 2017, 6, S1043-S1048.	1.0	O
128	Learning from Mistakes: An Error-Driven Mechanism to Improve Segmentation Performance Based on Expert Feedback. Lecture Notes in Computer Science, 2021, , 68-77.	1.3	0